Literature DB >> 26295744

Extracting the normal lung dose-response curve from clinical DVH data: a possible role for low dose hyper-radiosensitivity, increased radioresistance.

J J Gordon1, K Snyder, H Zhong, K Barton, Z Sun, I J Chetty, M Matuszak, R K Ten Haken.   

Abstract

In conventionally fractionated radiation therapy for lung cancer, radiation pneumonitis' (RP) dependence on the normal lung dose-volume histogram (DVH) is not well understood. Complication models alternatively make RP a function of a summary statistic, such as mean lung dose (MLD). This work searches over damage profiles, which quantify sub-volume damage as a function of dose. Profiles that achieve best RP predictive accuracy on a clinical dataset are hypothesized to approximate DVH dependence.Step function damage rate profiles R(D) are generated, having discrete steps at several dose points. A range of profiles is sampled by varying the step heights and dose point locations. Normal lung damage is the integral of R(D) with the cumulative DVH. Each profile is used in conjunction with a damage cutoff to predict grade 2 plus (G2+) RP for DVHs from a University of Michigan clinical trial dataset consisting of 89 CFRT patients, of which 17 were diagnosed with G2+ RP.Optimal profiles achieve a modest increase in predictive accuracy--erroneous RP predictions are reduced from 11 (using MLD) to 8. A novel result is that optimal profiles have a similar distinctive shape: enhanced damage contribution from low doses (<20 Gy), a flat contribution from doses in the range ~20-40 Gy, then a further enhanced contribution from doses above 40 Gy. These features resemble the hyper-radiosensitivity / increased radioresistance (HRS/IRR) observed in some cell survival curves, which can be modeled using Joiner's induced repair model.A novel search strategy is employed, which has the potential to estimate RP dependence on the normal lung DVH. When applied to a clinical dataset, identified profiles share a characteristic shape, which resembles HRS/IRR. This suggests that normal lung may have enhanced sensitivity to low doses, and that this sensitivity can affect RP risk.

Entities:  

Mesh:

Year:  2015        PMID: 26295744      PMCID: PMC4761430          DOI: 10.1088/0031-9155/60/17/6719

Source DB:  PubMed          Journal:  Phys Med Biol        ISSN: 0031-9155            Impact factor:   3.609


  29 in total

Review 1.  Radioresponsiveness at low doses: hyper-radiosensitivity and increased radioresistance in mammalian cells.

Authors:  K A Skov
Journal:  Mutat Res       Date:  1999-12-06       Impact factor: 2.433

2.  Alpha/beta ratio for normal lung tissue as estimated from lung cancer patients treated with stereotactic body and conventionally fractionated radiation therapy.

Authors:  Alize E H Scheenstra; Maddalena M G Rossi; José S A Belderbos; Eugène M F Damen; Joos V Lebesque; Jan-Jakob Sonke
Journal:  Int J Radiat Oncol Biol Phys       Date:  2014-01-01       Impact factor: 7.038

3.  Clinical evidence of hypersensitivity to low doses in radiotherapy.

Authors:  I Turesson; M C Joiner
Journal:  Radiother Oncol       Date:  1996-07       Impact factor: 6.280

4.  Low-dose radiation hyper-radiosensitivity in multicellular tumour spheroids.

Authors:  D Guirado; M Aranda; M Ortiz; J A Mesa; L I Zamora; E Amaya; M Villalobos; A M Lallena
Journal:  Br J Radiol       Date:  2012-10       Impact factor: 3.039

Review 5.  The tumor radiobiology of SRS and SBRT: are more than the 5 Rs involved?

Authors:  J Martin Brown; David J Carlson; David J Brenner
Journal:  Int J Radiat Oncol Biol Phys       Date:  2014-02-01       Impact factor: 7.038

6.  Modeling of normal tissue response to radiation: the critical volume model.

Authors:  A Niemierko; M Goitein
Journal:  Int J Radiat Oncol Biol Phys       Date:  1993-01       Impact factor: 7.038

7.  NTCP modelling of lung toxicity after SBRT comparing the universal survival curve and the linear quadratic model for fractionation correction.

Authors:  Berit M Wennberg; Pia Baumann; Giovanna Gagliardi; Jan Nyman; Ninni Drugge; Morten Hoyer; Anders Traberg; Kristina Nilsson; Elisabeth Morhed; Lars Ekberg; Lena Wittgren; Jo-Åsmund Lund; Nina Levin; Christer Sederholm; Rolf Lewensohn; Ingmar Lax
Journal:  Acta Oncol       Date:  2011-01-04       Impact factor: 4.089

8.  Impact of toxicity grade and scoring system on the relationship between mean lung dose and risk of radiation pneumonitis in a large cohort of patients with non-small cell lung cancer.

Authors:  Susan L Tucker; Hekun Jin; Xiong Wei; Shulian Wang; Mary K Martel; Ritsuko Komaki; H Helen Liu; Radhe Mohan; Yuhchyau Chen; James D Cox; Zhongxing Liao
Journal:  Int J Radiat Oncol Biol Phys       Date:  2009-10-14       Impact factor: 7.038

9.  A modelling study of the potential influence of low dose hypersensitivity on radiation treatment planning.

Authors:  Henriette B Honoré; Søren M Bentzen
Journal:  Radiother Oncol       Date:  2006-02-13       Impact factor: 6.280

10.  Three-times daily ultrafractionated radiation therapy, a novel and promising regimen for glioblastoma patients.

Authors:  Patrick Beauchesne
Journal:  Cancers (Basel)       Date:  2013-09-25       Impact factor: 6.639

View more
  3 in total

1.  Non-coplanar VMAT combined with non-uniform dose prescription markedly reduces lung dose in breath-hold lung SBRT.

Authors:  Jens Fleckenstein; Judit Boda-Heggemann; Kerstin Siebenlist; Tanya Gudzheva; Natallia Prakofyeva; Frank Lohr; Frederik Wenz; Anna Simeonova-Chergou
Journal:  Strahlenther Onkol       Date:  2018-05-25       Impact factor: 3.621

2.  Bioinformatics Analysis for Identifying Differentially Expressed MicroRNAs Derived from Plasma Exosomes Associated with Radiotherapy Resistance in Non-Small-Cell Lung Cancer.

Authors:  Lirong Zeng; Guilin Zeng; Zhong Ye
Journal:  Appl Bionics Biomech       Date:  2022-05-31       Impact factor: 1.664

3.  Plasma miRNAs in predicting radiosensitivity in non-small cell lung cancer.

Authors:  Xu Chen; Yanmei Xu; Xingyun Liao; Rongxia Liao; Luping Zhang; Kai Niu; Tao Li; Dezhi Li; Zhengtang Chen; Yuzhong Duan; Jianguo Sun
Journal:  Tumour Biol       Date:  2016-04-13
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.